Dr. Gigi Q. Chen, MD | Concord, CA ...

Dr. Gigi Q. Chen

Claim this profile

John Muir Medical Center-Concord Campus

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
14 drugs studied

Area of expertise

1Lung Cancer
Gigi Q. Chen has run 4 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I
2Non-Small Cell Lung Cancer
Gigi Q. Chen has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.
John Muir Medical Center-Concord Campus
Image of trial facility.
John Muir Medical Center-Walnut Creek

Clinical Trials Gigi Q. Chen is currently running

Image of trial facility.

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Gigi Q. Chen

Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Gigi Q. Chen has experience with
  • Biospecimen Collection
  • Crizotinib
  • Carboplatin
  • Gemcitabine Hydrochloride
  • Paclitaxel
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Gigi Q. Chen specialize in?
Is Gigi Q. Chen currently recruiting for clinical trials?
Are there any treatments that Gigi Q. Chen has studied deeply?
What is the best way to schedule an appointment with Gigi Q. Chen?
What is the office address of Gigi Q. Chen?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security